Acute Myeloblastic Leukemia
Conditions
Keywords
Lymphocytes CD4, Lymphocytes CCR7, ALLOGRAFT, Hematopoietic Stem Cells
Brief summary
This is a preclinical study prior to the establishment of a cell therapy protocol applicable to humans. The main objective is to evaluate the decrease in alloreactivity of TCD4 + population by partial selective depletion of CD4 + CCR7 + graft to less than 50 % of CD4 + totals. To test the alloreactivity of donor T lymphocytes.
Detailed description
This is a preclinical study prior to the establishment of a cell therapy protocol applicable to humans. The main objective is to evaluate the decrease in alloreactivity of TCD4 + population by partial selective depletion of CD4 + CCR7 + graft to less than 50 % of CD4 + totals. To test the alloreactivity of donor T lymphocytes , T lymphocytes CD4 + CCR7 + donor will be stimulated by mature dendritic cells (DC) derived from recipient circulating monocytes in a mixed lymphocyte reaction model sensitized ( MLDCR ) , experiencing HLA -compatibility . This first step will confirm the results previously obtained in a situation incompatible HLA .
Interventions
BIOLOGICALblood
assessment pre-donation of hematopoietic stem cells (blood sample)
Sponsors
University Hospital, Lille
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion criteria of the receiver anti -infectious immunity * Man or woman aged 18-65 years * Eligible for allo - HSCs from peripheral blood stem cells from a compatible donor HLA family (Annex 3 , the pre- transplant assessment must be enabled) * In a complete remission rate of leucocytes with ≥ 2G / L * Affiliated to social security person or beneficiary of such a scheme. * Having signed informed consent Inclusion criteria for the study of the receiver of anti tumor immunity * Man or woman aged 18-65 years * Achieved a hyperleucocytic acute myelogenous leukemia ( leukocytes ≥ 20G / L) * Patients whose blasts at diagnosis were cryopreserved in the tumor bank of the University Hospital of Lille (Professor Claude Prudhomme ) * Eligible for allo - HSCs from peripheral blood stem cells from a compatible donor HLA family (Annex 3 , the pre- transplant assessment must be enabled) * In a complete remission rate of leucocytes with ≥ 2G / L * Affiliated to social security person or beneficiary of such a scheme. * Having signed informed consent receivers Inclusion criteria of the donor * Man or woman aged 18-65 years * Member of the HLA-matched siblings and A, B, Cw, DR, DQ * Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled) * Having a rate of circulating lymphocytes ≥ 1 G / L * Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population * The statutes CMV and EBV are known (positive or negative). * Affiliated to social security person or beneficiary of such a scheme. who signed informed consent -
Exclusion criteria
Criteria for non inclusion of the pairs donor / Receiver * Private person of liberty by judicial or administrative decision * Person subject to a measure of legal protection * Pregnant or breastfeeding woman * People do not understand French or understanding with a disability. * Major Protected Person in emergency and refusing or unable to give informed consent At any time, individuals may request to be removed from the study Each subject may come out of the study by decision of the competent administrative authority of the promoter and the coordinating investigator but also by decision of a co-investigator or by decision of the interested himself in accordance with regulations and as mentioned in the form of obtaining consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change the lymphocyte proliferation will be evaluated using a scintillation spectrometer | 1 day, 5 day ,8 day | Decrease in alloreactivity of TCD4.(composite) Decrease population by partial selective depletion of CD4 + CCR7 + graft to less than 50% of total CD4 +will be evaluated on this basis criteria. |
| Change the functional properties of cells will be evaluated by T-SPOT TB®. | 1 day, 5 day ,8 day | Decrease in alloreactivity of TCD4.(composite) Decrease population by partial selective depletion of CD4 + CCR7 + graft to less than 50% of total CD4 +will be evaluated on this basis criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response to anti-infectious immunity | 24 months | Measure the anti-infectious immunity during a partial selective depletion of TCD4 + CCR7 + (≤ 50%) |
| Response to anti-tumor immunity | 24 months | Measure the anti-tumor immunity during a partial selective depletion of TCD4 + CCR7 + (≤ 50%) |
Countries
France
Outcome results
None listed